SCHEMBL942302

SCHEMBL942302

CC(=NNC(N)=S)c1ccsc1

nearest known ligand 0.66

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
METTL3 Q86U44 2/20 0.60
ATM Q13315 1/20 0.60
CTSL P07711 2/20 0.54
CTSK P43235 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL942301 1.00 METTL3 (0.60) METTL3ATMCTSLCTSK
SCHEMBL23794042 0.80 METTL3 (0.82) METTL3ATMCTSK
SCHEMBL28751452 0.80 CTSL (0.44) METTL3ATMCTSL
SCHEMBL9655158 0.78 LCK (0.50)
SCHEMBL9655163 0.78 LCK (0.50)
Acetophenone-Thiosemicarbazone SCHEMBL17666972 0.75 METTL3 (1.00) METTL3ATMCTSK
Phenyl(Methyl)Thiosemicarbazone SCHEMBL757506 0.75 METTL3 (1.00) METTL3ATMCTSK
Phenyl(Methyl)Thiosemicarbazone SCHEMBL14436799 0.75 METTL3 (1.00) METTL3ATMCTSK
SCHEMBL940794 0.74 METTL3 (0.72) METTL3ATMCTSK
SCHEMBL23515724 0.74 METTL3 (0.72) METTL3ATMCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318782-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-11-27 US disclosed
US-20110275827-A1 Mitotic Kinesin Inhibitor FUJIFILM CORPORATION (JP) 2011-11-10 US disclosed
EP-1454903-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-10-05 EP disclosed
EP-2327702-A1 Mitotic kinesin inhibitor Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
US-7902234-B2 Thiadiazoline derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-03-08 US disclosed
US-20110004000-A1 Mitotic Kinesin Inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-01-06 US disclosed
US-7851635-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-12-14 US disclosed
US-20100240716-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-09-23 US disclosed
EP-1454903-B1 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2010-09-08 EP disclosed
US-7759371-B2 Thiadiazoline derivative Kyowa Hakko Kinn Co., Ltd. (JP) 2010-07-20 US disclosed
US-20080207706-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD (JP) 2008-08-28 US disclosed
EP-1847534-A2 Thiadiazoline derivative Kyowa Hakko Kogyo Co., Ltd (JP) 2007-10-24 EP disclosed
US-20070213380-A1 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-09-13 US disclosed
US-20070155804-A1 Mitotic kinesin inhibitor KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN 2007-07-05 US disclosed
US-20060074113-A1 Thiadiazoline derivative KYOWA KIRIN CO., LTD. (JP) 2006-04-06 US disclosed
EP-1616866-A1 M-STAGE KINESIN INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-01-18 EP disclosed
US-20050113283-A1 Methods of treating conditions associated with an EDG-4 receptor MANIV ENERGY CAPITAL 2005-05-26 US disclosed
EP-1513522-A2 METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR SRI INTERNATIONAL (US) 2005-03-16 EP disclosed
EP-1454903-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-08 EP disclosed
WO-2003062392-A2 METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR CERETEK LLC (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074113-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 METTL3 2876/4885ATM 516/4885CTSL 4237/4885
US-20070155804-A1 Mitotic kinesin inhibitor KIF15, KIF5A, KIF5B METTL3 4203/4885ATM 648/4885CTSL 4128/4885
US-20070213380-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 METTL3 2876/4885ATM 516/4885CTSL 4237/4885
US-20110004000-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B METTL3 4203/4885ATM 648/4885CTSL 4128/4885
US-20100240716-A1 THIADIAZOLINE DERIVATIVE BRWD1, WDR82, RB1 METTL3 2787/4885ATM 651/4885CTSL 4395/4885
US-20050113283-A1 Methods of treating conditions associated with an EDG-4 receptor EDNRA, EDNRB, ESRRG METTL3 4123/4885ATM 4834/4885CTSL 1097/4885
US-20080207706-A1 THIADIAZOLINE DERIVATIVE BRWD1, RB1, ARG2 METTL3 2876/4885ATM 516/4885CTSL 4237/4885
US-20110275827-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B METTL3 4203/4885ATM 648/4885CTSL 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.